Sectors
The computational pathology technology provider has added $25m to a round co-led by Johnson & Johnson Innovation – JJDC.
Novo will exit the musculoskeletal disease drug developer, should the latter complete an initial public offering on the Nasdaq Global Market.
SR One is line for an exit from the small-molecule therapy developer, which has raised $170m in venture funding in the past year.
Astellas Venture Management is among the new investors in the cancer immunotherapy developer, which was spun off by PhoreMost four years ago.
Quench Bio will wind down after its protein target proved undruggable and will return capital to investors including AbbVie Ventures.
The Kaiser Permanente-backed healthcare engagement platform developer pushed its overall funding past $350m and its valuation to $3.2bn.
The pharmaceutical firm is joining forces with China International Capital Corporation, the investment bank with which it launched a $1bn fund in 2019.
Kakao Ventures and SK Holdings have returned to back the AI and data-infused drug discovery technology provider in a $44.5m round.
Ascension Ventures has closed its fifth fund at $285m with the backing of 13 health systems.
Ant Group has co-led a $154m round for the medical payments technology provider, which came a year after a China Re-backed series A-plus.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
